Seattle startup Intrinsic Medicine plans to go public through a merger with a shell company, Phoenix Biotech Acquisition Corp. The four-year old biotech startup is developing potential therapeutic compounds matching molecules found in human milk.
The deal is expected to raise $178.8 million through the special purpose acquisition company, known as a SPAC. The parties also will seek funding through a private placement, a financial mechanism that could lead to additional cash.
